Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

Published:2022-02 Issue:2 Volume:23 Page:292-303
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Cella David,Motzer Robert J,Suarez Cristina,Blum Steven I,Ejzykowicz Flavia,Hamilton Melissa,Wallace Joel F,Simsek Burcin,Zhang Joshua,Ivanescu Cristina,Apolo Andrea B,Choueiri Toni K

Funder

Bristol-Myers Squibb

Ipsen

Memorial Sloan Kettering Cancer Center

Takeda Pharmaceutical Co Ltd

Exelixis

Ono Pharmaceutical

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Towards individualized therapy for metastatic renal cell carcinoma;Kotecha;Nat Rev Clin Oncol,2019

2. Systemic therapy for metastatic renal-cell carcinoma;Choueiri;N Engl J Med,2017

3. The changing landscape of systemic therapy in metastatic renal cell carcinoma: an update;Gurram;Discov Med,2020

4. New first line treatment options of clear cell renal cell cancer patients with PD-1 or PD-L1 immune-checkpoint inhibitor-based combination therapies;Grimm;J Clin Med,2020

5. Updated European Association of Urology guidelines on renal cell carcinoma: Nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma;Bedke;Eur Urol,2021

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The FACT-GP5 as a global tolerability measure: responsiveness and robustness to missing assessments;Quality of Life Research;2024-07-24

2. The new era of lung cancer therapy: Combining immunotherapy with ferroptosis;Critical Reviews in Oncology/Hematology;2024-06

3. Excess Weight leads to a better Health-Related Quality of Life in patients with Cancer;2024-05-09

4. Tislelizumab combined with sunitinib in the treatment of metastatic clear cell renal cell carcinoma with renal venous tumor thrombus: A case report and literature review;Urology Case Reports;2024-05

5. Case report: Report of a rare encounter: metastasis of renal cell carcinoma to the thyroid;Frontiers in Oncology;2024-04-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3